A copy of the ESMO poster can be found on the Publications page of Checkpoint's website. In November 2024, Checkpoint received $9.2 million in cash proceeds through the exercise of existing warrants.

EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU- Interim data from inupadenant Phase 2 A2A-005 in ...

Also, the slides from the oral presentation given at the Society for Melanoma Research in September is available on our website and the upcoming poster, which will be presented ... we presented an ...

Q3 2024 Earnings Call Transcript November 7, 2024 4:30 AM ETCompany ParticipantsBruce Mackle - LifeSci Advisors, ...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious ...

Data from the squamous cell carcinoma of the head and neck cohort of this study were presented at the 2024 European Society for Medical Oncology congress in September ... The data presented in the ...

today announced a poster presentation at the upcoming 2024 European Society for Medical Oncology (ESMO) Annual Meeting to be held in Barcelona, Spain from September 13–17, 2024. Presentation ...

In July 2024, Checkpoint announced that the FDA accepted for review the resubmission of its BLA for cosibelimab as a complete response to the complete response letter (“CRL”) issued in December 2023 ...

The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD-1 inhibitor Jemperli (dostarlimab) – achieved a higher objective ...

Now, new data from the POD1UM-303 study reported at ESMO suggests the company could resurrect the SCAC indication and move Zynyz into the first-line setting to boot. Given in combination with ...

Nov. 6, 2024 — Children whose mothers took extra vitamin D during pregnancy continue to have stronger bones at age seven, according to ... Sewage Surveillance Proves Powerful in Combating ...

A Michigan State University researcher's new model for studying breast cancer could help scientists better understand why and where cancer metastasizes. A new randomized controlled trial out of ...